{"filing":{"accession_number":"0001411690-26-000040","cik":"0001411690","ticker":"BNGO","company_name":"Bionano Genomics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"bngo-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169026000040/bngo-20260624.htm"},"events":[{"id":13387,"run_id":11890,"accession_number":"0001411690-26-000040","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer of Bionano Genomics, effective July 20, 2026. This is a material executive appointment to a senior leadership role responsible for leading the company's global scientific strategy, innovation roadmap, and research initiatives. The appointment is material because it involves a key executive position at a company in the genomics sector where scientific leadership directly impacts competitive positioning and product development strategy.","company_name":"Bionano Genomics, Inc.","ticker":"BNGO","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10515,"accession_number":"0001411690-26-000040","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer of Bionano Genomics, effective July 20, 2026. This is a material executive appointment to a senior leadership role responsible for leading the company's global scientific strategy, innovation roadmap, and research initiatives. The appointment is material because it involves a key executive position at a company in the genomics sector where scientific leadership directly impacts competitive positioning and product development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:30:40.343369+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10515,"accession_number":"0001411690-26-000040","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer of Bionano Genomics, effective July 20, 2026. This is a material executive appointment to a senior leadership role responsible for leading the company's global scientific strategy, innovation roadmap, and research initiatives. The appointment is material because it involves a key executive position at a company in the genomics sector where scientific leadership directly impacts competitive positioning and product development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T12:30:40.343369+00:00","company_name":"Bionano Genomics, Inc.","ticker":"BNGO","filing_date":"2026-06-24"}]}